Dura Marta, Żuchowski Paweł, Gorgolewski Przemysław, Waszczak-Jeka Marzena, Jeka Sławomir
Department of Radiology and Imaging Diagnostics, Dr Jan Biziel University Hospital No. 2 in Bydgoszcz, Poland.
Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland.
Reumatologia. 2020;58(3):155-161. doi: 10.5114/reum.2020.96676. Epub 2020 Jun 29.
For many years, ultrasonography (US) has been a widely accepted modality used for joint assessment in patients with rheumatoid arthritis (RA). Given the efficacy of present day therapies, there is scepticism whether it is required in the first place. The most recent clinical Targeting synovitis in Early Rheumatoid Arthritis (TaSER) and Clinical Tight Control Therapy (ARCTIC) trials' results appear to contradict it, yet this does not necessarily mean ultrasound has no place in modern rheumatology. The possibility of detecting inflammation at a subclinical level carries a tremendous predictive value, enabling identification of patients likely to experience an exacerbation in the coming months. Therefore, US should be a part of the decision-making process regarding treatment modification or introduction of any additional interventions, such as glucocorticosteroid injections. The results of the most recent clinical trials do not negate the usefulness of US, but merely suggest that it ought to be used in moderation.
多年来，超声检查（US）一直是类风湿关节炎（RA）患者关节评估中广泛接受的一种方式。鉴于当今疗法的疗效，有人怀疑一开始是否需要进行超声检查。最新的早期类风湿关节炎滑膜炎靶向治疗（TaSER）和临床严格控制治疗（ARCTIC）试验结果似乎与之矛盾，但这并不一定意味着超声在现代风湿病学中没有用。在亚临床水平检测炎症的可能性具有巨大的预测价值，能够识别未来几个月可能病情加重的患者。因此，超声检查应成为治疗调整或引入任何额外干预措施（如糖皮质激素注射）决策过程的一部分。最近临床试验的结果并未否定超声检查的有用性，只是表明应该适度使用。
